Patents by Inventor Xichen Lin

Xichen Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10336719
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 2, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • Publication number: 20190010135
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 10, 2019
    Inventors: Weichun Chen, Ebere F. Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • Patent number: 10106515
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: October 23, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lingdong Zhu
  • Patent number: 10005731
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: June 26, 2018
    Assignee: Glaxo Group Limited
    Inventors: Fangbin Han, Hui Lei, Xichen Lin, Qinghua Meng, Yonghui Wang
  • Patent number: 9902715
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: February 27, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Jing Deng, Hui Lei, Xin Ma, Feng Ren, Wei Cai, Xichen Lin
  • Patent number: 9902735
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators of Formula (I) and their use in the treatment of diseases mediated by ROR?.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: February 27, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Jing Deng, Hui Lei, Xin Ma, Xichen Lin
  • Patent number: 9868724
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: January 16, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Hui Lei, Xin Ma, Feng Ren, Xichen Lin, Robert W. Marquis, Jr.
  • Publication number: 20170197978
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Application
    Filed: May 26, 2015
    Publication date: July 13, 2017
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jing DENG, Hui LEI, Xin MA, Xichen LIN
  • Publication number: 20170190681
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation
    Type: Application
    Filed: May 27, 2015
    Publication date: July 6, 2017
    Applicant: Glaxosmithline Intellectual Property Development Limited
    Inventors: Weichun CHEN, Ebere F. IGBOKO, Xichen LIN, Hongfu LU, Feng REN, Paul Bryan WREN, Zhongmiao XU, Ting YANG, Lingdong ZHU
  • Publication number: 20170121313
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Application
    Filed: May 26, 2015
    Publication date: May 4, 2017
    Inventors: Jing DENG, Hui LEI, Xin MA, Feng REN, Wei CAI, Xichen LIN
  • Publication number: 20170101399
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?
    Type: Application
    Filed: May 26, 2015
    Publication date: April 13, 2017
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Hui LEI, Xin MA, Feng REN, Xichen LIN, Robert W. MARQUIS, JR.
  • Publication number: 20150299121
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Application
    Filed: December 5, 2013
    Publication date: October 22, 2015
    Applicant: Glaxo Group Limited
    Inventors: Fangbin HAN, Hui LEI, Xichen LIN, Qinghua MENG, Yonghui WANG
  • Patent number: 8389508
    Abstract: The present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: March 5, 2013
    Assignee: Glaxo Group Limited
    Inventors: Guanghui Deng, Xichen Lin, Feng Ren, Baowei Zhao
  • Patent number: 8354406
    Abstract: The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: January 15, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Jianghe Deng, Jeffrey K. Kerns, Qi Jin, Guoliang Lin, Xichen Lin, Michael Lindenmuth, Christopher Neipp, Hong Nie, Sonia M Thomas, Katherine L. Widdowson
  • Patent number: 8354416
    Abstract: Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: January 15, 2013
    Assignee: Glaxo Group Limited
    Inventors: James F. Callahan, Jeffrey C. Boehm, Anthony William James Cooper, Stefano Livia, Paul Bamborough, Neysa Nevins, Zehong Wan, Beth A. Norton, Xichen Lin
  • Publication number: 20130012491
    Abstract: Disclosed are pyrimidine derivatives for use as a sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.
    Type: Application
    Filed: March 16, 2011
    Publication date: January 10, 2013
    Applicant: GLAXO GROUP LIMITED
    Inventors: Xichen Lin, Feng Ren, Haibo Zhang
  • Publication number: 20120283297
    Abstract: Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.
    Type: Application
    Filed: December 16, 2010
    Publication date: November 8, 2012
    Applicant: GLAXO WELLCOME HOUSE
    Inventors: James Bailey, Nigel Paul King, Xichen Lin, Feng Ren, Kheng-Chuan Tan, Sing Yeung Mak
  • Patent number: 8217028
    Abstract: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: July 10, 2012
    Assignee: Glaxo Group Limited
    Inventors: Jose Luis Castro Pineiro, Xichen Lin, Qian Liu, Kevin Meng, Feng Ren, David R Vesey, Baowei Zhao
  • Patent number: 8207176
    Abstract: The present invention is directed to novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds, compositions, and use in therapy as CSBP/RK/p38 kinase inhibitors of Formulas (V) and (Va) wherein inter alia, G5 and G6 are nitrogen and CH, provided that only one of G5 or G6 is nitrogen and the other is CH; R1 is C(Z)N(R10?)(CR10R20)vRb, C(Z)O(CR10R20)vRb, N(R10?)C(Z)(CR10R20)vRb, N(R10?)C(Z)N(R10?)(CR10R20)vRb, or N(R10?)OC(Z)(CR10R20)vRb; R1? is independently selected at each occurrence from halogen, C1-4 alkyl, halo-substituted-C1-4 alkyl, cyano, nitro, (CR10R20)v?NRdRd?, (CR10R20)v?C(O)R12, SR5, S(O)R5, S(O)2R5, or (CR10R20)v?OR13; Rb is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic, or heterocyclylC1-10 alkyl moiety, which moieties, excluding hydrogen, may all be optionally substituted; X is R2, OR2?, S(O)mR2?, (CH2)n?N(R10?)S(O)mR2?, (CH2)n?N(R10?)C(O)R2?, (CH2)n?NR4R14, (CH2)
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: June 26, 2012
    Assignee: Glaxo Group Limited
    Inventors: James F. Callahan, Jeffrey C. Boehm, Anthony William James Cooper, Stefano Livia, Paul Bamborough, Neysa Nevins, Zehong Wan, Beth A. Norton, Xichen Lin
  • Publication number: 20120101124
    Abstract: 1,2,4-Oxadiazol derivatives represented by formula (I) useful as sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated via S1P1 receptor are disclosed.
    Type: Application
    Filed: June 17, 2010
    Publication date: April 26, 2012
    Applicant: GLAXO GROUP LIMITED
    Inventors: Xichen Lin, Feng Ren, Yugui Si